William J. Maples

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

Keith C. Bible, Vera J. Suman, Julian R. Molina et al. · The Lancet Oncology · 2010 · 414 citations · Full text

Thyroid Cancers, Oncology, Medicine +11

Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis

Svetomir N. Markovic, Lori A. Erickson, Ravi D. Rao et al. · Mayo Clinic Proceedings · 2007 · 367 citations

Part 1, Cancer Risk, Cancer Epidemiology +13

The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs)

Lowell Anthony, Jonathan Strosberg, David S. Klimstra et al. · Pancreas · 2010 · 274 citations

Colorectal Surgery, Gastroenterology, Pathology +18

NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors

Alexandria T. Phan, Kjell Öberg, Junsung Choi et al. · Pancreas · 2010 · 198 citations

Surgical Oncology, Clinical Symptoms, Pathology +19

MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study

Timothy J. Hobday, Joseph Rubin, Kyle D. Holen et al. · Journal of Clinical Oncology · 2007 · 175 citations

Metastatic Net, Primary Endpoint, Pathology +19